TAS-106: preclinical, clinical and beyond.

@article{Abdelrahim2013TAS106PC,
  title={TAS-106: preclinical, clinical and beyond.},
  author={Maen Abdelrahim and Akira Matsuda and Aung S. Naing},
  journal={Oncology},
  year={2013},
  volume={85 6},
  pages={356-63}
}
5-Fluorouracil, other fluorinated pyrimidines and their derivatives are frequently used in chemotherapy to treat different types of cancer. These agents are classified as metabolic antagonists that target the DNA synthesis phase of the cell cycle. Therefore, these agents are more effective in rapidly growing tumors than in more indolent cancers. In order to develop new drugs that interfere with both DNA and RNA synthesis, the metabolism of pyrimidines was investigated, and new compounds were… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS